Thymosin Alpha-1 guide

At a glance

What the research says

The cited pharmacokinetic study compared three thymosin alpha-1 formulations in nine healthy volunteers. A crossover design examined single and five-day repeated subcutaneous administration. Researchers measured serum peptide and derived peak concentration, overall exposure, time to peak, clearance-related measures, and elimination half-life.[2]

Peak concentrations generally occurred within one to two hours, and elimination half-life was below three hours. The investigators found no clear accumulation over the repeated-administration period. Exposure differed among formulations, demonstrating why a generic peptide name alone does not fully specify a pharmacokinetic observation.[2]

The abstract's bound of less than three hours is distinct from the library's chosen 2.1-hour scalar. The separate Singapore product information supports a particular vial presentation and jurisdictional context. It does not turn the study into evidence of US approval or remove the formulation differences observed by the investigators.[2][1]

Cited amounts

The library records 1.6 mg as a labeled package amount. This is the total listed in that presentation, not an amount selected for administration. No personal dosing range is inferred from it.[1][4]

Half-life and timing

Using 2.1 hours makes the second halving occur at 4.2 hours and the fifth at 10.5 hours. The retained fractions are 25% and 3.125%. These are consequences of the representative input, not point estimates quoted from an abstract that only states a below-three-hour bound. The source's one- to two-hour concentration-peak range describes a different quantity. Neither the chosen scalar nor the peak range supplies missing absolute bioavailability or establishes a personal timing rule.[1][6]

Reconstitution

For an arithmetic illustration, 1.6 mg divided by an assumed final liquid volume of 2 mL gives 0.8 mg/mL. A hypothetical 0.1 mL would contain 0.08 mg, equal to 80 micrograms. The decimal conversions preserve mass across units; they do not establish an administration amount. Although the package is supported by licensed product information, the assumed volume is not presented as that product's preparation instruction. Label context, package quantity, and this mathematical assumption remain separately identified.[4]

Tracking it in PinPoint

Frequently asked questions

Is thymosin alpha-1's 2.1-hour half-life directly stated by the abstract?

The library says the abstract reports a half-life below three hours. Its stored 2.1 hours is a representative input within that context. The one- to two-hour peak range is a separate source-stated quantity, not the elimination half-life.[1][2]

Why is thymosin alpha-1's published bound different from a point estimate?

Below three hours defines an upper bound in the cited abstract, not an exact 2.1-hour observation. The latter is the stored representative model input. Preserving that difference prevents a convenient scalar from being attributed directly to the publication.[1][6]

Does Singapore package information imply FDA approval?

The library identifies the package's jurisdiction and separately says the compound is not FDA-approved. A licensed presentation outside the United States does not change that US status. The guide retains the source location rather than merging different regulatory contexts.[1][6]

Can a peptide tracker app record Thymosin Alpha-1?

PinPoint's compound library includes Thymosin Alpha-1. The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][5]

Sources

Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.

1. PinPoint compound library, Thymosin Alpha-1Snapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
2. PubMed pharmacology reference 10027483Identity and research summary checked against this document on 5 October 2026. PubMed abstract, retrieved through NCBI EFetch.Retrieved 2026-10-05 · library-reference
3. Published pharmacology referenceIdentity and research summary checked against this document on 5 October 2026. Abstract and relevant methods/results or product-monograph sections.Retrieved 2026-10-05 · library-reference
4. Labeled package referencePackage amount only; not a clinical amount or endorsement.Retrieved 2026-10-05 · label
5. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
6. Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic